Patents by Inventor Hiroyuki Mano

Hiroyuki Mano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11120541
    Abstract: A determination device that determines quality of target portion based on sensor data obtained by a sensor measuring the target object, includes one or more processors configured to acquire sensor data representing the target portion, acquire information indicating a changed portion, determine whether the target portion includes the changed portion based on acquired information, determine a first label of the target portion represented in the sensor data by using a determination model learned from a training dataset based on training target portions, the first label representing target portion as one of good, defect, and a defect candidate, accept a second label of the target portion input via a user interface when the target portion includes the changed portion or when the first label of the target portion is determined as the defect candidate, and perform quality determination of the target portion based on the first label and/or the second label.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: September 14, 2021
    Assignee: SEIKO EPSON CORPORATION
    Inventors: Kimitake Mizobe, Taro Tanaka, Natsumi Mano, Hiroyuki Masuda
  • Publication number: 20210262662
    Abstract: A method for controlling a catalytic combustion apparatus having a heater capable of heating fuel to be supplied to a catalyst includes a step of supplying oxidant gas to the catalytic combustion apparatus, and an injection step of injecting the fuel into the catalytic combustion apparatus. The injection step also includes an electric power feeding step of supplying electric power to the heater, and a setting step of setting an injection amount of the fuel to be injected into the catalytic combustion apparatus in response to output of the heater.
    Type: Application
    Filed: June 1, 2018
    Publication date: August 26, 2021
    Applicant: NISSAN MOTOR CO., LTD.
    Inventors: Susumu MAESHIMA, Tadaki MANO, Hiroyuki WADA, Masamitsu SATAKE
  • Publication number: 20210189383
    Abstract: It is an object of the present invention to provide, for instance, a method for evaluating a function, such as transforming potential, of multiple different genes of interest, and a method capable of evaluating drug sensitivity of a subject having each gene of interest.
    Type: Application
    Filed: March 30, 2018
    Publication date: June 24, 2021
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki MANO, Shinji KOHSAKA, Masachika IKEGAMI
  • Patent number: 10828377
    Abstract: An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 10, 2020
    Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, AICHI PREFECTURE, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Hiroyuki Mano, Toshihide Ueno, Takahiko Yasuda, Masahito Kawazu, Fumihiko Hayakawa, Hitoshi Kiyoi, Shinobu Tsuzuki, Tomoki Naoe
  • Publication number: 20200165687
    Abstract: It is an object of the present invention to provide a method for easily detecting a transcript resulting from a fusion gene and/or exon skipping. In one embodiment, the present invention relates to a probe set for determining the presence or expression level of a transcript of a fusion gene on the genome, a probe set for determining the presence or expression level of a transcript resulting from exon skipping, a kit comprising the probe set, a method for determining the presence or expression level of a transcript of a fusion gene on the genome by using the probe set, and a method for determining the presence or expression level of a transcript resulting from exon skipping.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 28, 2020
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki MANO, Shinji KOHSAKA, Toshihide UENO
  • Publication number: 20180318448
    Abstract: An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 8, 2018
    Inventors: Hiroyuki MANO, Toshihide UENO, Takahiko YASUDA, Masahito KAWAZU, Fumihiko HAYAKAWA, Hitoshi KIYOI, Shinobu TSUZUKI, Tomoki NAOE
  • Patent number: 9932589
    Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 3, 2018
    Assignees: ASTELLAS PHARMA INC., CUREGENE K.K.
    Inventors: Hiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
  • Publication number: 20180066266
    Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene.
    Type: Application
    Filed: November 13, 2017
    Publication date: March 8, 2018
    Applicants: Astellas Pharma Inc., CureGene K.K.
    Inventors: HIROYUKI MANO, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
  • Patent number: 9109259
    Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: August 18, 2015
    Assignees: Japanese Foundation for Cancer Research, Educational Foundation Jichi Medical University
    Inventors: Kengo Takeuchi, Yuichi Ishikawa, Hiroyuki Mano, Manabu Soda, Eirin Sai
  • Publication number: 20150185223
    Abstract: The present invention is based, in part, on the discovery of isolated nucleic acid molecules encoding mutant RAC polypeptides, or fragments thereof, wherein the mutant RAC polypeptides comprise one or more substitutions of an amino acid in the wild-type RAC polypeptide that renders the mutant RAC polypeptides constitutively active and oncogenic. Isolated mutant RAC polypeptides encoded by such nucleic acid molecules, as well as vectors, host cells, methods of producing encoded polypeptides using such isolated nucleic acid molecules, as well as methods of using mutant RAC nucleic acids and polypeptides for identifying, assessing, prognosing, and treating cancer, are also provided.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 2, 2015
    Inventors: Hiroyuki Mano, Masahito Kawazu, Kengo Takeuchi, Yoshio Miki, Toshihide Ueno
  • Publication number: 20150184161
    Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene.
    Type: Application
    Filed: March 10, 2015
    Publication date: July 2, 2015
    Applicants: Astellas Pharma Inc., CureGene K.K.
    Inventors: Hiroyuki MANO, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
  • Patent number: 9029521
    Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: May 12, 2015
    Assignees: Astellas Pharma Inc., Curegene K.K.
    Inventors: Hiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
  • Patent number: 9018230
    Abstract: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: April 28, 2015
    Assignee: Jichi Medical University
    Inventors: Hiroyuki Mano, Young L. Choi, Manabu Soda
  • Patent number: 8825385
    Abstract: An aspect of the invention is an information terminal device includes a widget management unit for managing execution of a widget being a monofunctional program for performing display on the display part of a display device. The widget management unit includes a policy determination unit for determining the operation policy, including operation restriction and priority, concerning a display state at the display device in the widget, and a reliability determining unit for determining the reliability representing the reliability of the widget in the widget. When the state of the movement calculated by a navigation unit becomes a preset state, the widget management unit regulates the display state of the widget according to the operation restriction and the reliability, and performs display, while preferentially displaying guidance state and positional information calculated by the navigation unit.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: September 2, 2014
    Assignee: Clarion Co., Ltd.
    Inventors: Shinya Iguchi, Tatsuaki Osafune, Takatoshi Kato, Kazutomo Kobayashi, Hiroyuki Mano, Hiroki Uchiyama
  • Publication number: 20130203810
    Abstract: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 8, 2013
    Inventors: Hiroyuki Mano, Young L. Choi, Manabu Soda
  • Publication number: 20130158095
    Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
    Type: Application
    Filed: May 10, 2012
    Publication date: June 20, 2013
    Applicants: CureGene K.K., Astellas Pharma Inc.
    Inventors: Hiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
  • Publication number: 20130102006
    Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.
    Type: Application
    Filed: June 22, 2011
    Publication date: April 25, 2013
    Applicants: Astellas Pharma Inc., Educational Foundation Jichi Medical University, Japanese Foundation For Cancer Research
    Inventors: Kengo Takeuchi, Yuichi Ishikawa, Hiroyuki Mano, Manabu Soda, Eirin Sai
  • Publication number: 20130096100
    Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 18, 2013
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yutaka KONDOH, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
  • Patent number: 8318702
    Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: November 27, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Yutaka Kondoh, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
  • Publication number: 20120253662
    Abstract: An aspect of the invention is an information terminal device includes a widget management unit for managing execution of a widget being a monofunctional program for performing display on the display part of a display device. The widget management unit includes a policy determination unit for determining the operation policy, including operation restriction and priority, concerning a display state at the display device in the widget, and a reliability determining unit for determining the reliability representing the reliability of the widget in the widget. When the state of the movement calculated by a navigation unit becomes a preset state, the widget management unit regulates the display state of the widget according to the operation restriction and the reliability, and performs display, while preferentially displaying guidance state and positional information calculated by the navigation unit.
    Type: Application
    Filed: November 2, 2010
    Publication date: October 4, 2012
    Applicant: CLARION CO., LTD.
    Inventors: Shinya Iguchi, Tatsuaki Osafune, Takatoshi Kato, Kazutomo Kobayashi, Hiroyuki Mano, Hiroki Uchiyama